# reload+after+2024-01-23 11:47:38.812566
address1§195 Church Street
address2§16th Floor
city§New Haven
state§CT
zip§06510
country§United States
phone§203 304 2499
website§https://www.trevitherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
fullTimeEmployees§25
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Jennifer L. Good', 'age': 58, 'title': 'Co-Founder, CEO, President & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 781850, 'exercisedValue': 0, 'unexercisedValue': 33222}, {'maxAge': 1, 'name': 'Dr. Thomas R. Sciascia M.D.', 'age': 70, 'title': 'Co-Founder & Chief Science Officer', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 530475, 'exercisedValue': 0, 'unexercisedValue': 25316}, {'maxAge': 1, 'name': 'Dr. David J. Clark A.F.P.M., M.D., M.R.C.P.', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 325386, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lisa  Delfini', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher  Galletta', 'age': 45, 'title': 'Controller & Chief Accounting Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Katie  McManus', 'title': 'Communications Manager', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Farrell  Simon Pharm.D.', 'title': 'Chief Commercial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Danine  Summers', 'age': 65, 'title': 'Vice President of Medical Affairs', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§9
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.6
currency§USD
dateShortInterest§1702598400
forwardEps§-0.41
exchange§NGM
quoteType§EQUITY
shortName§Trevi Therapeutics, Inc.
longName§Trevi Therapeutics, Inc.
firstTradeDateEpochUtc§1557235800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8a113135-b079-3dd8-b58f-6d658f375d63
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§6.0
targetMeanPrice§7.33
targetMedianPrice§7.5
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§6
quickRatio§17.179
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
